[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582059":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":40,"locations":46,"responsibleParty":60,"collaborators":24,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":24,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":24,"enrollmentInfo":71,"targetDuration":24,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":48,"whyStopped":24,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"RAK Medical and Health Sciences University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Pharmacist-Led Educational Intervention","EXPERIMENTAL","Physicians and patients in this arm will receive a multi-faceted pharmacist-led educational intervention. This includes evidence-based deprescribing guidelines, brochures, videos, and decision aids to promote appropriate use of PPIs and reduce unnecessary prescriptions. The intervention is delivered in four parts: educational brochures, deprescribing algorithm, patient action plans, and video-based education sessions.",[13],"Other: Pharmacist-Led Educational Intervention",{"label":15,"type":6,"description":16,"interventionNames":17},"Control","Participants in this arm will continue with their usual care without any pharmacist-led intervention during the 6-month study period. Physicians and patients will follow the standard clinical practice for PPI prescriptions.",[18],"Other: Control (Standard treatment)",[20,25],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"Control (Standard treatment)","Participants in this arm will continue with their usual care without any pharmacist-led intervention during the 6-month study period. Physicians and patients will follow the standard clinical practice for PPI prescriptions. At the end of the 6-month period, the educational materials provided to the intervention group will be offered to the control group.",[15],null,{"type":6,"name":9,"description":11,"armGroupLabels":26,"otherNames":24},[9],[28,31,33,35,37],{"name":29,"affiliation":5,"role":30},"Syed Arman Rabbani","PRINCIPAL_INVESTIGATOR",{"name":32,"affiliation":5,"role":30},"Mohamed El-Tanani",{"name":34,"affiliation":5,"role":30},"Imran Rashid Rangraze",{"name":36,"affiliation":5,"role":30},"Sathvik B Sridhar",{"name":38,"affiliation":39,"role":30},"Arwa Alnahdi","Ibrahim Bin Hamad Obaidullah Hospital",[41],{"name":29,"role":42,"phone":43,"phoneExt":44,"email":45},"CONTACT","+971 7 2043000","230","arman@rakmhsu.ac.ae",[47],{"facility":39,"status":48,"city":49,"state":24,"zip":24,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Ras al-Khaimah","United Arab Emirates","AE",{"type":53,"coordinates":54},"Point",[55,56],55.9432,25.78953,{"lat":56,"lon":55},[59],{"name":29,"role":42,"phone":43,"phoneExt":44,"email":45},{"type":30,"investigatorFullName":29,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Professor Syed Arman Rabbani","100582059","rak-pride-optimizing-proton-pump-inhibitor-use-through-education-and-intervention-100582059",false,"NCT06858384","RAK-PRIDE: Optimizing Proton Pump Inhibitor Use Through Education and Intervention","From Awareness to Action: Transforming Proton Pump Inhibitor Use in Ras Al Khaimah Through Education and Intervention: the RAK -PRIDE Study","Inclusion Criteria:\n\nPhysicians will be eligible to participate if:\n\n* They are prescribing PPIs in outpatient department of the study sites\n* They have patients with potentially inappropriate PPI prescriptions\n\nPatients will be eligible to participate if:\n\n* They are ≥18 years\n* They are presenting to out-patient departments of the study sites\n* They have prescriptions of potentially inappropriate PPIs\n* Their treating physicians are included in the study\n\nExclusion Criteria:\n\nPhysicians will be excluded if:\n\n• They are involved in any other prescribing trial\n\nPatients will be excluded if:\n\n* They are unable to give informed consent, as judged by their physicians\n* They have definitive indications for PPI use","ALL","18 Years",{"count":72,"type":73},479,"ESTIMATED","INTERVENTIONAL",[76],"NA","The goal of this study is to determine if a pharmacist-led educational intervention can reduce the inappropriate use of proton pump inhibitors (PPIs) among adult patients (≥18 years) with potentially inappropriate PPI prescriptions in Ras Al Khaimah.\n\nThe main questions it aims to answer are:\n\n* Can a pharmacist-led education program reduce unnecessary PPI use?\n* Does the intervention improve patients' quality of life and reduce healthcare costs? Researchers will compare the intervention group (receiving pharmacist-led education and materials) to the usual care group to see if the intervention reduces PPI use and improves patient outcomes.\n\nParticipants will:\n\n* Receive educational materials from pharmacists, including a patient educational brochure, PPI patient decision aid, PPI deprescribing pamphlet, and PPI patient action plan.\n* Physicians involved will also receive a pharmaceutical intervention, which includes a physician educational brochure, PPI evidence-based deprescribing guideline, PPI deprescribing algorithm, and whiteboard videos on PPI deprescribing.\n* Patients will be followed up for 6 months to monitor changes in PPI use, symptoms, and quality of life.",[79,80,81],"Proton Pump Inhibitors","Deprescribing","Inappropriate Use",[83,84,80,85,86,87],"proton pump inhibitors","peptic ulcer disease","pharmacist-led educational intervention","inappropriate use","RAK - PRIDE","2025-03-08",{"date":90,"type":91},"2025-03-12","ACTUAL",{"date":93,"type":73},"2025-03",{"date":95,"type":73},"2026-02",{"name":5,"class":6},1]